Table 2.

Detection of tumor-reactive antibodies in the A20 lymphoma model

GroupMice% reactivity with A20 cells
(preimmune sera)
% reactivity with A20 cells
(sera after vaccination on day 40)
Vaccination treatment
40 Application of intact bsAb BiLu and irradiated tumor cells 
 46  
 18  
 29  
 28  
 30  
Application of intact bsAb BiLu and irradiated tumor cells;
depletion of CD4+ T cells 
 14  
  
 10  
 11  
 12 15  
13 Application of bsF(ab′)2 fragments and irradiated tumor cells 
 14  
 15  
 16  
 17  
 18  
19 Control: application of irradiated tumor cells without antibody 
 20  
 21  
 22  
 23  
 24  
GroupMice% reactivity with A20 cells
(preimmune sera)
% reactivity with A20 cells
(sera after vaccination on day 40)
Vaccination treatment
40 Application of intact bsAb BiLu and irradiated tumor cells 
 46  
 18  
 29  
 28  
 30  
Application of intact bsAb BiLu and irradiated tumor cells;
depletion of CD4+ T cells 
 14  
  
 10  
 11  
 12 15  
13 Application of bsF(ab′)2 fragments and irradiated tumor cells 
 14  
 15  
 16  
 17  
 18  
19 Control: application of irradiated tumor cells without antibody 
 20  
 21  
 22  
 23  
 24  

bsAb indicates bispecific antibody.

Sera of immunized BALB/c mice were assessed for tumor-reactive antibodies by flow-activated cell sorter analysis as described in “Materials and methods.” The reaction is shown as the percentage of positively stained tumor cells. P < .0023 for the differences between group A and the other groups B-D, by the Mann-Whitney U test.

Close Modal

or Create an Account

Close Modal
Close Modal